Triple therapy (ICS/LABA/LAMA) in COPD: time for a reappraisal

Triple therapy (ICS/LABA/LAMA) in COPD: time for a reappraisal

Lowie Vanfleteren,1–3 Leonardo M Fabbri,1,4 Alberto Papi,4 Stefano Petruzzelli,5 Bartolome Celli6 1COPD Center, Institute of Medicine, Sahlgrenska University Hospital, University of Gothenburg, Gothenburg, Sweden; 2CIRO, Horn, the Netherlands; 3Department of Respiratory Medicine, Maastric...

Full description

Bibliographic Details
Main Authors:	Vanfleteren L, Fabbri LM, Papi A, Petruzzelli S, Celli B
Format:	Article
Language:	English
Published:	Dove Medical Press 2018-12-01
Series:	International Journal of COPD
Subjects:	Muscarinic antagonists adrenergic beta-2 receptor agonists glucocorticoids pulmonary disease chronic obstructive review exacerbations safety
Online Access:	https://www.dovepress.com/triple-therapy-icslabalama-in-copd-time-for-a-reappraisal-peer-reviewed-article-COPD

Similar Items

Extrafine triple therapy delays COPD clinically important deterioration vs ICS/LABA, LAMA, or LABA/LAMA
by: Singh D, et al.
Published: (2019-02-01)

Maintenance therapy in COPD: time to phase out ICS and switch to the new LAMA/LABA inhalers?
by: Tariq SM, et al.
Published: (2017-06-01)

Patient-reported outcomes of dual bronchodilator fixed-dose combination versus bronchodilator monotherapy in individuals with COPD
by: Strange C, et al.
Published: (2019-06-01)

Comparative efficacy of inhaled medications (ICS/LABA, LAMA, LAMA/LABA and SAMA) for COPD: a systematic review and network meta-analysis
by: Abdul Aziz MI, et al.
Published: (2018-10-01)

When to Use Initial Triple Therapy in COPD: Adding a LAMA to ICS/LABA by Clinically Important Deterioration Assessment
by: Cheng WC, et al.
Published: (2020-12-01)

Patient Characteristics and Healthcare Resource Utilization Among Patients with COPD New to LAMA/LABA Fixed-Dose Combination Treatment in US-Based Real-World Practice
by: Ding B, et al.
Published: (2020-04-01)

Comparison of Dry-Powder Inhaler and Pressurized Metered-Dose Inhaler Formulations of Extrafine Beclomethasone Dipropionate/Formoterol Fumarate/Glycopyrronium in Patients with COPD: The TRI-D Randomized Controlled Trial
by: Beeh KM, et al.
Published: (2021-01-01)

Long-acting muscarinic antagonists vs. long-acting β 2 agonists in COPD exacerbations: a systematic review and meta-analysis
by: Israel Silva Maia, et al.

Treatment after a COPD exacerbation
by: Robbins RA
Published: (2013-07-01)

Effectiveness and Tolerability of LABA/LAMA Fixed-Dose Combinations Aclidinium/Formoterol, Glycopyrronium/Indacaterol and Umeclidinium/Vilanterol in the Treatment of COPD in Daily Practice – Results of the Non-Interventional DETECT Study
by: Plate T, et al.
Published: (2020-06-01)

Impact and prevention of severe exacerbations of COPD: a review of the evidence
by: Halpin DMG, et al.
Published: (2017-10-01)

Triple versus LAMA/LABA combination therapy for patients with COPD: a systematic review and meta-analysis
by: Akira Koarai, et al.
Published: (2021-06-01)

Overactive bladder – 18 years – Part II
by: Jose Carlos Truzzi, et al.
Published: (2016-04-01)

Overactive bladder – 18 years – part I
by: Jose Carlos Truzzi, et al.
Published: (2016-04-01)

Triple Therapy of Fluticasone Furoate, Umeclidinium, Vilanterol- A Compelling Choice in Severe Chronic Obstructive Pulmonary Disease
by: B Jagan Nathan, et al.
Published: (2021-02-01)

COPD from an everyday primary care point of view
by: Antonio L Aguilar-Shea, et al.
Published: (2019-01-01)

Predicting treatable traits for long-acting bronchodilators in patients with stable COPD
by: Kang J, et al.
Published: (2017-12-01)

Triple therapy (ICS/LABA/LAMA) in COPD: thinking out of the box
by: Lowie E.G.W. Vanfleteren, et al.
Published: (2019-02-01)

Randomized dose-finding study of batefenterol via dry powder inhaler in patients with COPD
by: Crim C, et al.
Published: (2019-03-01)

Evidence-based review of data on the combination inhaler umeclidinium/vilanterol in patients with COPD
by: Albertson TE, et al.
Published: (2019-06-01)

Management of chronic obstructive pulmonary disease: Insights into patient profile – Use of inhaled corticosteroids/long-acting β2-Agonists or long-acting β2-agonists/long-acting muscarinic antagonists
by: Nevin Kishore, et al.
Published: (2020-01-01)

Experience of using double bronchodilation therapy in patients with COPD
by: I. V. Demko, et al.
Published: (2021-01-01)

Dose-response relationship of ICS/fast-onset LABA as reliever therapy in asthma
by: Richard Beasley, et al.
Published: (2019-12-01)

Determinants of response to inhaled extrafine triple therapy in asthma: analyses of TRIMARAN and TRIGGER
by: Dave Singh, et al.
Published: (2020-10-01)

LABA in patients with stage I COPD and mild sleep apnea syndrome: a pilot study
by: Kopitovic Ivan, et al.
Published: (2011-02-01)

Forced Expiratory Flow (FEF25–75%) as a Clinical Endpoint in Children and Adolescents with Symptomatic Asthma Receiving Tiotropium: A Post Hoc Analysis
by: Stanley J. Szefler, et al.
Published: (2020-05-01)

Improved lung function and patient-reported outcomes with co-suspension delivery technology glycopyrrolate/formoterol fumarate metered dose inhaler in COPD: a randomized Phase III study conducted in Asia, Europe, and the USA
by: Lipworth BJ, et al.
Published: (2018-09-01)

Salivary Protein Components and Oral Health in Patients Undergoing Therapy with Beta Adrenegic Agonist and Antagonist
by: Tahani A Al–Sandook, et al.
Published: (2008-08-01)

Tiotropium in chronic obstructive pulmonary disease – a review of clinical development
by: Antonio Anzueto, et al.
Published: (2020-07-01)

Effects of Empirical Glucocorticoid Use on Severe Acute Exacerbation of COPD During Hospitalization
by: Wu L, et al.
Published: (2021-08-01)

The effects of oral administration of the novel muscarinic receptor antagonist DA-8010 on overactive bladder in rat with bladder outlet obstruction
by: Jin Bong Choi, et al.
Published: (2020-04-01)

First-Line Treatment with Tiotropium/Olodaterol Improves Physical Activity in Patients with Treatment-Naïve Chronic Obstructive Pulmonary Disease
by: Takahashi K, et al.
Published: (2020-09-01)

Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler Improves Lung Function versus Monotherapies in GOLD Category A Patients with COPD: Pooled Data from the Phase III PINNACLE Studies
by: Martinez FJ, et al.
Published: (2020-01-01)

Drug Design Targeting the Muscarinic Receptors and the Implications in Central Nervous System Disorders
by: Bergman, J., et al.
Published: (2022)

24-h bronchodilation and inspiratory capacity improvements with glycopyrrolate/formoterol fumarate via co-suspension delivery technology in COPD
by: Colin Reisner, et al.
Published: (2017-08-01)

Once-daily single-inhaler versus twice-daily multiple-inhaler triple therapy in patients with COPD: lung function and health status results from two replicate randomized controlled trials
by: Gary T. Ferguson, et al.
Published: (2020-05-01)

Combinations of long acting β2 agonists to tiotropium: A randomized, double-blind, placebo-controlled, active-drug controlled, parallel design academic clinical trial in moderate COPD male patients
by: Mohammed Imran, et al.
Published: (2015-01-01)

A phase IIb randomized, chronic-dosing, incomplete block, cross-over study of glycopyrronium, delivered via metered dose inhaler, compared with a placebo and an active control in patients with moderate-to-severe COPD
by: Edward M. Kerwin, et al.
Published: (2018-03-01)

Practical considerations when prescribing a long-acting muscarinic antagonist for patients with COPD
by: D’Urzo AD, et al.
Published: (2018-04-01)

Relationship of inhaled long-acting bronchodilators with cardiovascular outcomes among patients with stable COPD: a meta-analysis and systematic review of 43 randomized trials
by: Li CX, et al.
Published: (2019-04-01)

Cannot write session to /tmp/vufind_sessions/sess_k7tau0pi6lb5omkc9rgjemkcda